TNFRSF10A (TRAIL-R1/DR4) is a death receptor that mediates extrinsic apoptosis upon binding the cytotoxic ligand TRAIL 1. Upon activation, the adapter molecule FADD recruits caspase-8 to form a death-inducing signaling complex (DISC), initiating a caspase cascade that triggers programmed cell death 2. TNFRSF10A also promotes NF-κB activation, contributing to both apoptotic and inflammatory responses 3. Transcriptional regulation of TNFRSF10A involves the stress-responsive proteins DDIT3 and KAT2A, which cooperatively enhance receptor expression during endoplasmic reticulum stress in cancer cells 1. Clinically, TNFRSF10A represents a therapeutic vulnerability in pancreatic ductal adenocarcinoma (PDAC), where aberrantly elevated expression correlates with tumor progression and has been identified as a target for drug repurposing approaches 4. However, TRAIL-based therapies face significant challenges due to TRAIL resistance in many cancer populations, which involves complex interplay between death receptor abundance, decoy receptor expression, and intracellular anti-apoptotic mechanisms 5. While TRAIL-R1 selectively induces apoptosis in tumor cells with minimal effects on normal tissues, endothelial cells can experience TRAIL-mediated injury and inflammatory responses 6, highlighting the need for careful therapeutic consideration.